We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the FLAGLSX-Forensic Accounting Long-Short Index. The investment seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the FLAGLSX-Forensic Accounting Long-Short Index.
SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...
Calidi common stock expected to begin trading on a 1-for-10 split adjusted basis on July 15, 2024 Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or “Company”), a clinical-stage...
Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the...
Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, is pleased to...
Calidi’s best-in-class, novel systemic targeted virotherapy program (RTNova) aims to provide a feasible solution to target disseminated tumors with a systemic administration -- a long-pursued...
- NeuroNova (CLD-101) Phase 1 update highlights enrollment progress, safety and feasibility in delivering up to four weekly doses of CLD-101 - Showcased preclinical data on RTNova (CLD-400...
Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the...
Three upcoming posters, including an update from ongoing Phase 1 trial of Calidi’s CLD-101 program, to be presented at 2024 ASCO Annual Meeting Presented new data on the mechanisms of action of...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.22 | -12.2222222222 | 1.8 | 1.95 | 1.575 | 617012 | 1.69034641 | CS |
| 4 | -0.472 | -23.0019493177 | 2.052 | 2.198 | 1.414 | 866223 | 1.67622627 | CS |
| 12 | -0.394 | -19.959473151 | 1.974 | 4.9 | 1.414 | 1310982 | 2.15107235 | CS |
| 26 | -7.92 | -83.3684210526 | 9.5 | 16.8 | 1.414 | 1089494 | 3.14009567 | CS |
| 52 | -43.52 | -96.4966740576 | 45.1 | 50 | 1.414 | 653463 | 3.98247392 | CS |
| 156 | -43.52 | -96.4966740576 | 45.1 | 50 | 1.414 | 653463 | 3.98247392 | CS |
| 260 | -43.52 | -96.4966740576 | 45.1 | 50 | 1.414 | 653463 | 3.98247392 | CS |
Monksdream
6 days ago
ErnieBilco
3 weeks ago
JTORENCE
3 weeks ago
Invest-in-America
2 months ago
Termite7
2 months ago
accipiterr
2 months ago
accipiterr
3 months ago
ErnieBilco
3 months ago
Legend431
4 months ago
Triple nickle
4 months ago
2020trader
4 months ago
glenn1919
5 months ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
